Gilead Sciences's new hepatitis C treatment, Sovaldi, had $3.48 billion in second-quarter sales, more than expected, continuing its historic drug launch.

Topics:  gilead sciences   sovaldi   c   hepatitis   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News